Search Medical Condition
Please enter condition
Please choose location

Hennebont, France Clinical Trials

A listing of Hennebont, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (22) clinical trials

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of patients with AML. The outcome of first line chemotherapy treatment is poor and many patients fail to attain complete remission ...

Phase

1.39 miles

Learn More »

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, ...

Phase

1.39 miles

Learn More »

Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome

The Overlap Syndrome is defined by the coexistence of chronic obstructive pulmonary disease (COPD) and an apnea - hypopnea syndrome obstructive sleep (SAHS). The interaction between these two diseases is responsible for deepest nocturnal desaturation, decreased sensitivity to CO2, more pronounced sleep alterations, more frequent daytime hypercapnia, a higher risk ...

Phase N/A

1.39 miles

Learn More »

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

ROSCO-CF is a phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa. The aim of this study is to assess ...

Phase

1.39 miles

Learn More »

A Phase III of ADT +/- Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-na ve Prostate Cancer.

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked. The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone), arm C(ADT + radiotherapy) or arm D (ADT + ...

Phase

1.39 miles

Learn More »